Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug Response.


Journal

Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R

Informations de publication

Date de publication:
01 04 2021
Historique:
received: 16 01 2020
revised: 25 12 2020
accepted: 03 02 2021
pubmed: 10 2 2021
medline: 12 8 2021
entrez: 9 2 2021
Statut: ppublish

Résumé

Insights into oncogenesis derived from cancer susceptibility loci (SNP) hold the potential to facilitate better cancer management and treatment through precision oncology. However, therapeutic insights have thus far been limited by our current lack of understanding regarding both interactions of these loci with somatic cancer driver mutations and their influence on tumorigenesis. For example, although both germline and somatic genetic variation to the p53 tumor suppressor pathway are known to promote tumorigenesis, little is known about the extent to which such variants cooperate to alter pathway activity. Here we hypothesize that cancer risk-associated germline variants interact with somatic

Identifiants

pubmed: 33558336
pii: 0008-5472.CAN-20-0177
doi: 10.1158/0008-5472.CAN-20-0177
pmc: PMC10266546
mid: NIHMS1904355
doi:

Substances chimiques

Antineoplastic Agents 0
Biomarkers, Pharmacological 0
TP53 protein, human 0
Tumor Suppressor Protein p53 0

Types de publication

Journal Article Meta-Analysis Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1667-1680

Subventions

Organisme : Intramural NIH HHS
ID : Z01 ES100475
Pays : United States
Organisme : Medical Research Council
ID : MC_PC_12006
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/17/35/32929
Pays : United Kingdom
Organisme : NIH HHS
ID : DP5 OD017937
Pays : United States
Organisme : Medical Research Council
ID : MC_UU_00001/6
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : T32 CA067754
Pays : United States
Organisme : Cancer Research UK
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M016587/1
Pays : United Kingdom

Informations de copyright

©2021 American Association for Cancer Research.

Références

Nat Rev Cancer. 2003 Feb;3(2):117-29
pubmed: 12563311
Nat Genet. 2017 Jul;49(7):1133-1140
pubmed: 28604728
Cell. 2012 Feb 3;148(3):409-20
pubmed: 22304912
Physiol Rev. 2012 Oct;92(4):1619-49
pubmed: 23073628
J Mol Biol. 2017 Jun 2;429(11):1595-1606
pubmed: 28390900
Nat Genet. 2020 May;52(5):494-504
pubmed: 32341527
Nat Rev Cancer. 2016 Apr;16(4):251-65
pubmed: 27009395
Nat Commun. 2018 Sep 7;9(1):3636
pubmed: 30194396
Nat Rev Urol. 2016 Jul;13(7):409-19
pubmed: 27296647
Clin Cancer Res. 2008 Nov 1;14(21):6821-8
pubmed: 18980976
Cell. 2017 Feb 9;168(4):566-570
pubmed: 28187278
Oncogene. 2015 Nov 12;34(46):5729-38
pubmed: 25728675
Nat Rev Mol Cell Biol. 2015 Jul;16(7):393-405
pubmed: 26122615
Nat Genet. 2017 May;49(5):680-691
pubmed: 28346442
Mol Cell. 2020 Feb 6;77(3):681
pubmed: 32032511
Nat Methods. 2013 Oct;10(10):965-71
pubmed: 24161985
Science. 2015 Oct 9;350(6257):207-211
pubmed: 26359337
Nat Commun. 2015 Dec 22;6:10086
pubmed: 26689913
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Am J Pathol. 2010 Jun;176(6):2607-15
pubmed: 20395447
PLoS One. 2012;7(5):e37776
pubmed: 22662219
Cancer Res. 2011 Dec 1;71(23):7168-75
pubmed: 21983037
Nat Rev Cancer. 2012 Sep;12(9):587-98
pubmed: 22918414
J Clin Oncol. 2006 Sep 10;24(26):4340-6
pubmed: 16908931
Nat Genet. 2010 Jul;42(7):604-7
pubmed: 20543847
Pigment Cell Melanoma Res. 2014 Jan;27(1):8-10
pubmed: 24118922
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Oncotarget. 2017 Jan 31;8(5):8921-8946
pubmed: 27888811
Am J Hematol. 2014 Mar;89(3):282-7
pubmed: 24779033
Cancer Discov. 2017 Apr;7(4):410-423
pubmed: 28188128
Br J Dermatol. 1993 Jun;128(6):606-11
pubmed: 8338744
Nat Rev Drug Discov. 2008 Dec;7(12):979-87
pubmed: 19043449
Cell. 2017 Sep 7;170(6):1062-1078
pubmed: 28886379
Blood. 2013 Sep 12;122(11):1900-13
pubmed: 23896410
Cell. 1993 Sep 24;74(6):957-67
pubmed: 8402885
Pigment Cell Res. 2003 Jun;16(3):287-96
pubmed: 12753403
Nat Genet. 2013 Jun;45(6):580-5
pubmed: 23715323
Nat Genet. 2011 Sep 25;43(11):1098-103
pubmed: 21946351
Nucleic Acids Res. 2019 Jan 8;47(D1):D1005-D1012
pubmed: 30445434
Nat Commun. 2019 Nov 7;10(1):5061
pubmed: 31699989
Cell. 2013 Oct 10;155(2):410-22
pubmed: 24120139
Bioinformatics. 2010 Sep 1;26(17):2190-1
pubmed: 20616382
Trends Pharmacol Sci. 2014 Jan;35(1):41-50
pubmed: 24361003
Cell. 2018 Apr 5;173(2):400-416.e11
pubmed: 29625055
Oncogene. 2017 Jul 13;36(28):3943-3956
pubmed: 28288132
Cell. 2004 Dec 17;119(6):847-60
pubmed: 15607980
Cancer Cell. 2013 May 13;23(5):618-33
pubmed: 23623661
Nat Commun. 2020 Sep 4;11(1):4423
pubmed: 32887889
Nat Genet. 2020 Jun;52(6):572-581
pubmed: 32424353
Nat Rev Cancer. 2012 Apr 05;12(5):349-61
pubmed: 22475929
Genes Dev. 2008 May 15;22(10):1337-44
pubmed: 18483220
Pharmacol Rev. 2006 Sep;58(3):621-81
pubmed: 16968952
Cell. 2004 Dec 17;119(6):861-72
pubmed: 15607981
J Clin Invest. 2010 Oct;120(10):3594-605
pubmed: 20811155
PLoS Biol. 2004 Feb;2(2):E40
pubmed: 14966536
Nat Protoc. 2013 Nov;8(11):2281-2308
pubmed: 24157548
Nature. 2017 Nov 2;551(7678):92-94
pubmed: 29059683
Science. 1997 Jan 17;275(5298):343-9
pubmed: 8994024
Cancer Cell. 2014 Mar 17;25(3):304-17
pubmed: 24651012
Cell. 2017 Nov 16;171(5):1029-1041.e21
pubmed: 29056346
Apoptosis. 2010 May;15(5):608-20
pubmed: 20094798
Cell. 2016 Jul 28;166(3):740-754
pubmed: 27397505

Auteurs

Ping Zhang (P)

Ludwig Institute for Cancer Research, University of Oxford, Nuffield Department of Clinical Medicine, Old Road Campus Research Building, Oxford, United Kingdom.

Isaac Kitchen-Smith (I)

Ludwig Institute for Cancer Research, University of Oxford, Nuffield Department of Clinical Medicine, Old Road Campus Research Building, Oxford, United Kingdom.

Lingyun Xiong (L)

Ludwig Institute for Cancer Research, University of Oxford, Nuffield Department of Clinical Medicine, Old Road Campus Research Building, Oxford, United Kingdom.

Giovanni Stracquadanio (G)

Ludwig Institute for Cancer Research, University of Oxford, Nuffield Department of Clinical Medicine, Old Road Campus Research Building, Oxford, United Kingdom.

Katherine Brown (K)

Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom.

Philipp H Richter (PH)

Ludwig Institute for Cancer Research, University of Oxford, Nuffield Department of Clinical Medicine, Old Road Campus Research Building, Oxford, United Kingdom.

Marsha D Wallace (MD)

Ludwig Institute for Cancer Research, University of Oxford, Nuffield Department of Clinical Medicine, Old Road Campus Research Building, Oxford, United Kingdom.

Elisabeth Bond (E)

Ludwig Institute for Cancer Research, University of Oxford, Nuffield Department of Clinical Medicine, Old Road Campus Research Building, Oxford, United Kingdom.

Natasha Sahgal (N)

Ludwig Institute for Cancer Research, University of Oxford, Nuffield Department of Clinical Medicine, Old Road Campus Research Building, Oxford, United Kingdom.

Samantha Moore (S)

Ludwig Institute for Cancer Research, University of Oxford, Nuffield Department of Clinical Medicine, Old Road Campus Research Building, Oxford, United Kingdom.

Svanhild Nornes (S)

Ludwig Institute for Cancer Research, University of Oxford, Nuffield Department of Clinical Medicine, Old Road Campus Research Building, Oxford, United Kingdom.

Sarah De Val (S)

Ludwig Institute for Cancer Research, University of Oxford, Nuffield Department of Clinical Medicine, Old Road Campus Research Building, Oxford, United Kingdom.

Mirvat Surakhy (M)

Ludwig Institute for Cancer Research, University of Oxford, Nuffield Department of Clinical Medicine, Old Road Campus Research Building, Oxford, United Kingdom.

David Sims (D)

Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom.

Xuting Wang (X)

Environmental Epigenomics and Disease Group, Immunity, Inflammation, and Disease Laboratory, National Institute of Environmental Health Sciences-National Institutes of Health, Research Triangle Park, North Carolina.

Douglas A Bell (DA)

Environmental Epigenomics and Disease Group, Immunity, Inflammation, and Disease Laboratory, National Institute of Environmental Health Sciences-National Institutes of Health, Research Triangle Park, North Carolina.

Jorge Zeron-Medina (J)

Ludwig Institute for Cancer Research, University of Oxford, Nuffield Department of Clinical Medicine, Old Road Campus Research Building, Oxford, United Kingdom.
Sarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, United Kingdom.

Yanyan Jiang (Y)

CRUK & MRC Oxford Institute for Radiation Oncology, University of Oxford, Department of Oncology, Old Road Campus Research Building, Oxford, United Kingdom.

Anderson J Ryan (AJ)

CRUK & MRC Oxford Institute for Radiation Oncology, University of Oxford, Department of Oncology, Old Road Campus Research Building, Oxford, United Kingdom.

Joanna L Selfe (JL)

Sarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, United Kingdom.

Janet Shipley (J)

Sarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, United Kingdom.

Siddhartha Kar (S)

Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.

Paul D Pharoah (PD)

Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.

Chey Loveday (C)

Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom.

Rick Jansen (R)

Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Psychiatry, Amsterdam Neuroscience, the Netherlands.

Lukasz F Grochola (LF)

Department of Surgery, Cantonal Hospital Winterthur, Switzerland.

Claire Palles (C)

Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom.

Andrew Protheroe (A)

Oxford Cancer and Haematology Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.

Val Millar (V)

Target Discovery Institute, University of Oxford, Nuffield Department of Medicine, Oxford, United Kingdom.

Daniel V Ebner (DV)

Target Discovery Institute, University of Oxford, Nuffield Department of Medicine, Oxford, United Kingdom.

Meghana Pagadala (M)

Department of Medicine, University of California, San Diego, La Jolla, California.

Sarah P Blagden (SP)

Department of Oncology, University of Oxford, Oxford, United Kingdom.

Timothy S Maughan (TS)

Department of Oncology, University of Oxford, Oxford, United Kingdom.

Enric Domingo (E)

Department of Oncology, University of Oxford, Oxford, United Kingdom.

Ian Tomlinson (I)

Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom.

Clare Turnbull (C)

Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom.

Hannah Carter (H)

Department of Medicine, University of California, San Diego, La Jolla, California. G.Bond.1@bham.ac.uk hkcarter@health.ucsd.edu.

Gareth L Bond (GL)

Ludwig Institute for Cancer Research, University of Oxford, Nuffield Department of Clinical Medicine, Old Road Campus Research Building, Oxford, United Kingdom. G.Bond.1@bham.ac.uk hkcarter@health.ucsd.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH